FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Ratchets Up Heat on 7-OH Products

FDA recommends placing 7-hydroxymitragynine (7-OH) a highly concentrated, synthetic byproduct of the kratom plant under the Controlled Substances Act...

latest-news-card-1
Human Drugs

Shiva Contract Lab CGMP Violations

FDA warns Indias Shiva Analyticals Private Limited about CGMP violations in its work as a contract testing laboratory.

latest-news-card-1
Human Drugs

Quality Management Benefits Exceed Costs: FDA Paper

The CDER Office of Pharmaceutical Quality publishes a white paper making the economic case for quality management practices.

latest-news-card-1
Human Drugs

Antibacterial Therapies Q&A Guidance

FDA issues a question-and-answer guidance on the development of certain antibacterial therapies.

latest-news-card-1
Human Drugs

PTC Therapeutics Phenylketonuria Drug Approved

FDA approves a PTC Therapeutics NDA for Sephience (sepiapterin), indicated for treating adult and pediatric patients with phenylketonuria, a rare inhe...

latest-news-card-1
FDA General

User Fee Rates Set for FY 2026

FDA posts the user fee rates for fiscal year 2026 for prescription drugs and biologics, biosimilar, medical devices and generic drugs.

Medical Devices

Multiple Violations at Onkos Surgical

FDA warns Parsippany, NJ-based Onkos Surgical about Quality System and Medical Device Reporting violations in its work as a medical device specificati...

latest-news-card-1
Human Drugs

CGMP Deviations in Macsen Drugs Inspection

FDA warns Indias Macsen Drugs about CGMP deviations in its production of active pharmaceutical ingredients.

latest-news-card-1
Human Drugs

Recognify Reports Mixed Data on Schizophrenia Drug

Recognify Life Sciences says its Phase 2b trial of inidascamine, a drug candidate for treating cognitive impairment associated with schizophrenia, did...

latest-news-card-1
Human Drugs

Input Sought on Controversial Menopause Expert Panel

After being criticized for attempting to bypass a formal advisory committee review of warnings associated with hormone replacement therapies, FDA anno...